Q-omics provides the consensus-scored MED12L profile across patient tissues and cancer cell-line models. MED12L expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, MED12L is differentially expressed in 10, with the highest sampling consensus in HNSC. Additionally, MED12L RNA expression shows 19,590 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight BLCA, HNSC, and UVM as cancer lineages where MED12L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MED12L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MED12L survival associations across molecular data types. MED12L RNA expression shows survival associations in the most cancer types (24), followed by mutation status (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MED12L RNA expression–survival associations across cancer types. High MED12L expression shows unfavorable associations in BLCA and STAD, but favorable associations in BRCA, SCLC, SKCM and PAAD. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify BLCA as the clearest survival context for MED12L RNA expression.
This table summarizes MED12L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 1. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for MED12L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MED12L shows lower tumor expression in COAD and higher tumor expression in HNSC, LUSC, KIRC, BRCA and PRAD. The HNSC box plot shows higher MED12L RNA expression in tumor versus normal tissue (log2 FC = +0.351, t-test p < 0.001).
This table shows molecular features associated with MED12L in patient tissues and cancer cell lines. In patient samples, MED12L shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, MED12L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
